Form 4: Pulse Biosciences CCO Exercises Options, Sells Shares

Pulse Biosciences' Chief Commercial Officer, Kevin Patrick Danahy, exercised stock options and subsequently sold 4,600 shares of common stock under a pre-arranged trading plan.

Summary

• Kevin Patrick Danahy, Chief Commercial Officer of Pulse Biosciences, Inc. (PLSE), engaged in transactions involving the company's common stock.
• On October 2, 2025, Mr. Danahy exercised stock options to acquire 4,600 shares of common stock at an exercise price of $1.53 per share.
• Immediately following the option exercise on the same date, Mr. Danahy sold 4,600 shares of common stock at a weighted average price of $18.53 per share.
• The sale price per share ranged from $18.48 to $18.65.
• Both the option exercise and the subsequent sale were conducted pursuant to a Rule 10b5-1 trading plan, which was adopted by Mr. Danahy on May 14, 2025.
• After these transactions, Mr. Danahy's direct beneficial ownership of common stock stands at 43,298 shares.
• He also continues to beneficially own 425,000 derivative securities in the form of stock options.

Sentiment

Score: 4

Explanation: The Chief Commercial Officer exercised options and sold shares for a significant profit, which is a personal financial decision. While insider selling can sometimes be viewed negatively, these transactions were pre-planned under a Rule 10b5-1 plan, mitigating immediate concerns about company prospects. The remaining option holdings are substantial, indicating continued alignment with shareholder interests.

Positives

• The Chief Commercial Officer realized a significant profit from the exercise of stock options and subsequent sale of shares, demonstrating personal financial gain from company equity.
• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a structured and pre-determined approach to managing equity rather than a reactive sale based on new information.

Negatives

• Insider selling, even under a 10b5-1 plan, can sometimes be perceived by the market as a lack of conviction in the company's near-term stock price appreciation, although this is a personal financial decision.

Future Outlook

This Form 4 filing is a report of insider transactions and does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing details an individual insider's equity transactions, which are part of personal financial planning and compensation. It does not provide direct insights into broader industry trends or competitive positioning, but rather reflects an executive's management of their equity holdings.

Comparison to Industry Standards

• This Form 4 reports individual insider transactions and does not contain financial or operational results that can be directly compared to global industry benchmarks, comparable companies, or specific projects.

Stakeholder Impact

• Shareholders: A minor increase in the number of shares outstanding due to option exercise (offset by sale) and potential, albeit limited, market perception from insider selling. The pre-planned nature mitigates significant concern.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

The filing details a routine insider transaction where the Chief Commercial Officer exercised options and sold a portion of the resulting shares under a pre-arranged 10b5-1 plan. This is primarily a personal financial event for profit realization and does not provide new fundamental information about the company's operational performance or future prospects. While insider selling can sometimes be a yellow flag, the pre-planned nature and the relatively small scale compared to total holdings suggest it's not a strong indicator for a 'sell' recommendation. Investors should 'hold' and look for more substantive operational or financial updates to inform investment decisions.

Keywords

Pulse Biosciences, PLSE, Insider Trading, Form 4, Stock Option Exercise, Share Sale, Kevin Patrick Danahy, Chief Commercial Officer, 10b5-1 Plan